1. Introduction {#sec0005}
===============

Measles viruses (MeV) are enveloped, pleomorphic particles that belong to the family of *Paramyxoviridae* \[[@bib0005],[@bib0010]\]. They harbor one or more copies of a non-segmented RNA genome of negative polarity and exhibit a natural lymphotropism in humans and primates \[[@bib0015], [@bib0020], [@bib0025]\]. Wild-type MeV uses CD150/SLAMF1 as an attachment receptor for entering different immune cells (macrophages, dendritic cells, activated or memory B and T cells) and Nectin-4/PVRL4 on cells of the airway epithelium to exit the host *via* the respiratory route \[[@bib0030], [@bib0035], [@bib0040]\]. Natural infection with wild-type MeV causes measles, a disease that is still responsible for more than 100,000 deaths per year worldwide, despite the availability of a safe and effective vaccine \[[@bib0045],[@bib0050]\]. Attenuated, replication-competent vaccine strains of MeV exhibit a natural oncotropism and have thus been explored as novel anti-tumor therapeutics. Their dual mechanism of action includes direct lysis of infected cancer cells along with the release of tumor-associated antigens and the induction of an immunostimulatory tumor microenvironment. In addition to their excellent safety record and natural oncotropism, the possibility of multi-level genetic engineering makes MeV a promising oncolytic virus (OV) candidate ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1**Targeting, arming, and stealthing of oncolytic MeV. a)** Targeting and tumor-specificity of oncolytic MeV can be engineered on multiple levels. Entry targeting: Shown here is a fully-retargeted MeV that recognizes tumor antigens *via* scFv fused to the MeV H protein. Post-entry targeting: Displayed is an oncolytic MeV carrying target sites for microRNAs which are present in healthy cells but lost in malignant cells. This microRNA-controlled MeV is strongly attenuated in healthy cells expressing cognate microRNAs, but remains fully effective against tumor cells. **b)** Oncolytic MeV can be engineered to encode therapeutic transgenes. **c)** Stealthing of oncolytic MeV. Left: Pseudotyping of MeV with the envelope glycoproteins of a closely related paramyxovirus (canine distemper virus, CDV). Right: To avoid neutralization by pre-existing anti-MeV antibodies, it is possible to shield the individual virions using a polymeric envelope structure.Fig. 1

While next-generation oncolytic MeV are being developed pre-clinically, the first generation of recombinant MeV vaccine strains are already being tested in phase I/II clinical trials \[[@bib0055],[@bib0060]\]. Recently reported data from the first trials are promising, with early indications of safety and anti-tumor activity \[[@bib0065], [@bib0070], [@bib0075], [@bib0080]\].

In this review, we will give an overview of genetic engineering strategies and combination therapies with oncolytic MeV. We will use the acronym TASC-MeV to structure this review and will discuss [t]{.ul}argeting, [a]{.ul}rming, and [s]{.ul}tealthing of oncolytic MeV, as well as [c]{.ul}ombination therapies and [me]{.ul}asles virus as a [v]{.ul}accine platform. For further details on the mechanisms of oncolytic immunotherapy using measles virus, we refer the reader to the review article by Pidelaserra-Martí and Engeland in this special issue on oncolytic immunotherapy.

2. Targeting {#sec0010}
============

When considering the use of replication-competent viruses as therapeutic agents for the treatment of cancer, tumor specificity is of critical importance to ensure both patient safety and therapeutic efficacy. OVs that are highly effective against a given cancer but lack tumor specificity resulting in substantial off-target replication and toxicity have limited to no clinical applicability. Likewise, OVs that may bind to many different cell types or that get sequestered in, for example, the liver might not reach the tumor in sufficient numbers, thus limiting their efficacy, especially when administered systemically. To address the issue of tumor-specificity, two main approaches have been employed: the selection of viruses with natural oncotropism, and the genetic modification of viruses resulting in engineered tumor specificity. A third option, the use of cell carriers with tumor-homing capabilities, will be discussed in the chapter "Stealthing and neutralizing antibodies".

In MeV-based virotherapy, both natural oncotropism and engineered tumor-specificity come into play. The natural oncotropism of MeV has been first described in a well-known case report of a young boy whose Burkitt's lymphoma regressed following infection with wild-type MeV \[[@bib0085]\]. The molecular basis for the natural tumor selectivity of MeV is primarily based on its receptor usage and its sensitivity towards the anti-viral interferon (IFN) response, which is often compromised in cancer cells. It should be noted that most of the pre-clinical and clinical constructs currently used in MeV-based virotherapy are derived from vaccine strains of MeV, which differ from the wild-type viruses not only in terms of pathogenicity but also in terms of receptor usage and ability to antagonize the IFN response. Wild-type strains utilize CD150/SLAM-F1 \[[@bib0040],[@bib0090]\] and Nectin-4/PVRL-4 \[[@bib0030],[@bib0035]\] as entry receptors, with the vaccine strains additionally using CD46/MCP \[[@bib0095],[@bib0100]\]. CD150/SLAM-F1 is overexpressed on many hematological malignancies (including the aforementioned Burkitt's lymphoma \[[@bib0105]\]), while CD46/MCP (a negative regulator of complement activity) is constitutively overexpressed on a wide variety of tumor cells \[[@bib0110]\]. Interestingly, some of the vaccine strains (incl. the Edmonston-B strain, from which MeV currently used in clinical trials are derived) carry mutations in the phosphoprotein (*P)* gene, which dampens their ability to control the host's anti-viral IFN response \[[@bib0115], [@bib0120], [@bib0125], [@bib0130], [@bib0135], [@bib0140]\]. Since the IFN response is frequently dysregulated in malignant cells, this accounts - at least in part - for the preferential replication of vaccine-strain MeV in transformed cells.

Genetically engineered oncolytic MeV have been made possible by the development and refinement of a reverse genetics system allowing virus rescue from cloned DNA \[[@bib0145],[@bib0150]\].

Engineered tumor-specificity, also referred to as "targeting", has been achieved on the entry and post-entry level. In the case of entry-targeting, recognition of the natural receptor is prohibited by altering the amino acids responsible for receptor binding within the hemagglutinin (*H*) gene. In a second step, a novel tropism is conveyed by genetic fusion of targeting ligands to the "blinded" *H* gene. A variety of targeting molecules have been successfully tested, including different kinds of antibodies \[[@bib0155], [@bib0160], [@bib0165], [@bib0170], [@bib0175], [@bib0180], [@bib0185]\], DARPins \[[@bib0190],[@bib0195]\], or ligands for cytokine/growth factor/cell membrane receptors \[[@bib0200],[@bib0205]\]. In the case of post-entry targeting, microRNA target sites and artificial riboswitches have been explored. Global loss of microRNA expression levels in healthy *versus* malignant cells is an emerging hallmark of cancer and can be exploited by engineering OVs for increased tumor specificity. For this concept, target sequences of microRNAs which are lost in tumor cells, but expressed in healthy tissues, are inserted into the OV genome \[[@bib0210], [@bib0215], [@bib0220], [@bib0225], [@bib0230]\]. We have shown that this approach suppresses oncolytic MeV in microRNA-expressing healthy tissues, while replication kinetics and subsequent destruction of cancer cells remains unchanged \[[@bib0235], [@bib0240], [@bib0245]\].

Finally, it is possible to engineer inactive MeV, to be activated in the tumor microenvironment (TME) before exerting any cytotoxic activity. This can be achieved by the insertion of ectopic protease cleavage sites into the MeV F protein, as described by Springfeld et al. and Muehlebach et al. \[[@bib0250],[@bib0255]\] By selecting cleavage motifs recognized by proteases frequently overexpressed and secreted by cancer cells (*e.g.*, matrix metalloproteinase 2), preferential activation of oncolytic MeV in the TME can be achieved. Apart from this distinct activation of MeV in the TME, temporal particle inactivation can be achieved using small molecule-inducible ribozyme switches. These riboswitches can be engineered as RNA-based ON or OFF switches, and have been used by Ketzer et al. to design DNA-based OVs (adenoviruses) and RNA-based OVs (MeV) which are "switched off" by the addition of a small molecule riboswitch activator \[[@bib0260]\]. This genome modification adds another layer of safety, similarly to entry-targeted or microRNA-controlled oncolytic MeV.

3. Arming {#sec0015}
=========

With the development of reverse genetics and rescue system \[[@bib0145],[@bib0150]\], MeV vaccine strains have become a powerful tool for transgene delivery. Three different attenuated MeV constructs have been administered to cancer patients in clinical trials, one unmodified, and two encoding reporter transgenes, the sodium iodide symporter (NIS) and carcinoembryonic antigen (CEA) \[[@bib0075],[@bib0080],[@bib0265]\]. A strong argument is to be made that future clinical trials will yield even better patient outcomes with the introduction of therapeutic transgenes. Though only demonstrated in pre-clinical models, NIS has the supplementary function as a therapeutic transgene in radiovirotherapy by driving intracellular uptake of ^131^I isotopes in infected cells \[[@bib0270]\]. Synergy between MeV-NIS and ^131^I radiotherapy has been shown in mice with subcutaneous human xenografts of pancreatic adenocarcinoma, medulloblastoma, prostate cancer, squamous cell carcinoma of the head and neck, and anaplastic thyroid cancer \[[@bib0270], [@bib0275], [@bib0280], [@bib0285], [@bib0290]\]. MeV-NIS has also been engineered to co-express IFN-beta, which led to enhanced infiltration of the tumor by innate immune cells as well as superior tumor control and overall survival in murine xenograft models of mesothelioma \[[@bib0295]\]. This approach leverages the capacity of OVs to express a given protein locally in cancer cells. Similarly, tumor-restricted activation of chemotherapeutics has been explored using prodrug convertases. Early experiments with virally-encoded prodrug convertases used *Escherichia coli* purine nucleoside phosphorylase (PNP) in conjunction with fludarabine to concentrate toxic ATP analogs in cancer cells \[[@bib0160],[@bib0165],[@bib0300]\]. Due to toxicity concerns from systemic fludarabine administration, the foundation of current chemovirotherapeutic strategies uses super cytosine deaminase (SCD/CD-UPRT), a fusion protein of yeast-derived cytosine deaminase and uracil phosphoribosyltransferase \[[@bib0305], [@bib0310], [@bib0315], [@bib0320]\]. SCD converts the prodrug 5-fluorocystosine into 5-fluorouracil then 5-fluorouridine monophosphate (5-FUMP). This process occurs exclusively in cancer cells due to the tumor-restricted expression of SCD. Cellular enzymes in cancer cells then process 5-FUMP into toxic metabolites that interfere with DNA repair, as well as DNA, RNA, and protein synthesis, leading to enhanced tumoricidal bystander effects \[[@bib0315]\].

The recent body of pre-clinical transgene research has had an emphasis on immunomodulation. Specifically, transgenes that strengthen the host's immune response against the tumor are desirable. Following the observation that MeV was a suitable candidate as an OV, Grote et al. suspected that the host inflammatory response, particularly neutrophils, contributed to its therapeutic effect \[[@bib0325]\]. To address this, the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) was encoded into MeV to potentiate neutrophil functions. In a SCID mouse model of human lymphoma, MeV encoding murine GM-CSF outperformed unmodified MeV, and its efficacy correlated with neutrophil infiltration in the tumor \[[@bib0325]\]. SCID mice lack B- and T-cells; therefore, the adaptive immune response towards the therapy was not analyzed. This was revisited using an immunocompetent murine colon adenocarcinoma model using MC38cea cells permissive to retargeted MeV-antiCEA \[[@bib0330]\]. In this study, we demonstrated that MeV-antiCEA armed with GM-CSF not only enhanced the median overall survival, but also led to a durable complete remission in one third of the mice. Mice treated with MeV-GM-CSF-antiCEA rejected tumors upon re-challenge, demonstrating an adaptive memory immune response with lasting protection \[[@bib0330]\]. GM-CSF as an OV transgene has effectively translated into the clinic as it is utilized in the first globally approved oncolytic virus Talimogene laherparepvec.

Immune checkpoint inhibitors are a breakthrough cancer immunotherapy that enable persistent activation of tumor-infiltrating lymphocytes (TILs); for this and other reasons, OVs are an ideal partner for combination therapy. OVs attract cytotoxic T lymphocytes to the tumor and upregulate the expression of PD-L1 on both cancer and immune cells \[[@bib0335],[@bib0340]\]. In an attempt to combine MeV with immune checkpoint inhibition (ICI), we have virally-encoded PD-L1 and CTLA-4 antibodies and found that MeV virotherapy was greatly enhanced by ICI in an immunocompetent melanoma mouse model \[[@bib0345]\]. This demonstrated synergy between the two treatment modalities and showed how they can be engineered into a single, functional monotherapy. Bi-specific T-cell engagers (BiTEs) are another strategy to engage TILs toward cancer cells. BiTEs are covalently linked single-chain variable fragments with dual specificity for T-cells and a desired tumor antigen, thereby bringing them in proximity to form an artificial immunological synapse \[[@bib0350]\]. We have shown in a B16-CD20-CD46 mouse model that MeV encoding CD3xCD20 BiTEs cause a significant increase in CD8^+^ TILs and induce a protective anti-tumor immunity \[[@bib0355]\]. In another study, MeV-encoded IL-12 likewise enhanced the abundance of CD8^+^ TILs, and depletion experiments showed this T-cell subtype was crucial for its efficacy \[[@bib0360]\]. When comparing several immunomodulatory transgenes including IL-12, IP-10, a soluble form of CD80, GM-CSF, and PD-L1/CTLA-4 antibodies, the PD-L1 antibody- and IL-12- armed viruses were superior in their respective experiments \[[@bib0360]\]. MeV encoding IL-12 also showed a superior anti-tumor efficacy in MC38cea and B16-hCD46 tumor models when compared to an IL-15-encoding variant \[[@bib0365]\]. Finally, MeV encoding tumor-associated antigens have been engineered as an oncolytic vaccine platform, and shown to successfully prime and activate CD8^+^ T cells \[[@bib0370]\].

4. Stealthing and neutralizing antibodies {#sec0020}
=========================================

While oncolytic MeV offers many advantages as a therapeutic agent (most notably its excellent safety profile along with the possibility for multi-level genetic engineering), a major hurdle to its use systemically are pre-existing neutralizing antibodies. This is the case since most people in the western population have been previously immunized against this virus to confer immunity towards the pathogenic strain \[[@bib0375],[@bib0380]\]. This poses a challenge for systemic administration of the virus since the neutralizing antibodies may bind and neutralize the virus before it reaches the tumor location \[[@bib0385]\]. A clinical trial of intraperitoneal MeV treatment in ovarian cancer patients that had neutralizing antibodies towards MeV was encouraging; however, it was hypothesised that the results could be improved by removing the pre-existing neutralizing antibodies \[[@bib0070]\]. This was likely due to the success of a disseminated myeloma clinical trial that utilized systemic administration of MeV in patients with no neutralizing antibodies towards the virus \[[@bib0065]\]. While these results are promising, as mentioned previously, the majority of the western population is immunized against MeV; therefore, many novel strategies have emerged to circumvent this potential obstacle. One such approach is pseudotyping, the substitution of envelope glycoproteins of one virus with another. Since MeV neutralizing antibodies recognize and achieve neutralization *via* binding to the F and H glycoproteins of MeV \[[@bib0380]\], exchanging these proteins with those of a closely related virus which the general population has not been exposed to would confer humoral immune evasion to the administered pseudotyped MeV.

Pseudotyping MeV for the goal of evading neutralizing antibodies has been achieved with several viruses with varying degrees of success. Measles was successfully pseudotyped with the closely related canine distemper virus (CDV) and was able to evade anti-MeV neutralizing antibodies \[[@bib0390],[@bib0395]\]. Miest et al. demonstrated that the CDV-pseudotyped MeV had similar oncolytic properties to the original MeV. On the other hand, pseudotyping MeV with the Tupaia virus, also from the *Paramyxoviridae* family, generated a virus that was too attenuated and was no longer a viable oncolytic therapy \[[@bib0400]\]. It was also attempted to generate an H glycoprotein that will evade neutralization by inducing point mutations in typical antibody binding sites. While this was successful in stealthing a retargeted version of H, it was not effective for the endogenous form indicating shared epitopes for viral entry and antibody neutralization warranting the need for further insight on the matter \[[@bib0405]\].

Another approach for stealthing oncolytic MeV from neutralizing antibodies is to employ infected cell carriers. The concept is to infect designated cells with MeV and then administer this complex systemically. Once the infected cells reach the tumor location either passively or actively *via* cytokine homing \[[@bib0410]\], MeV spreads to the tumor *via* heterogeneous cell-cell fusion \[[@bib0415]\]. The infected cell carriers have been shown to protect its oncolytic cargo from circulating neutralizing antibodies \[[@bib0420]\]. Many types of cell carriers have been tested with oncolytic MeV, including transformed cells \[[@bib0425]\], mesenchymal stem cells \[[@bib0420]\], macrophages \[[@bib0430]\], dendritic cells \[[@bib0435]\], and T cells \[[@bib0415]\]. Apart from the choice of carrier cells, the particulars of the manufacturing process, such as loading dose and time \[[@bib0440]\], will likely influence the therapeutic efficacy achieved by this strategy.

Moreover, MeV stealthing has been achieved *via* a chemical modification - coating the virus particle with polyethylene glycol \[[@bib0445]\]. This was done with layer-by-layer deposition of ionic polymers at the MeV surface. Not only did the coated virus have better oncolytic capacity in the presence of neutralizing antibodies, but it also demonstrated better anti-tumor activity *in vivo* than the unmodified virus. A similar strategy was employed by Xia et al., where they coated the particle surface with graphene oxide and obtained similar results with the coated virus displaying superior tumor-killing ability in the presence of MeV neutralizing antibodies *versus* its bare counterpart \[[@bib0450]\].

Indirect strategies for overcoming MeV neutralizing antibodies have also been explored. Administration of immunosuppressors such as cyclophosphamide (CPA) prior to MeV treatment caused a drastic decrease in anti-MeV neutralizing antibodies in an *in vivo* mouse model \[[@bib0455]\] and resulted in enhanced oncolytic activity \[[@bib0300]\]. CPA acts by killing proliferating lymphocytes, thus ablating the humoral anti-viral response if administered following proper guidelines as outlined by Peng et al. \[[@bib0455]\]. A second approach that has been investigated *in vitro* is the use of UV-inactivated MeV prior to administration of the therapeutically active virus \[[@bib0460]\]. This effectively acts as a decoy for sequestering the pre-existing anti-MeV antibodies and might in turn boost the efficacy of the active virus administered shortly thereafter. While this depletion of anti-MeV antibodies might be an effective strategy *in vitro*, it remains to be seen if such a regimen can be translated safely into the clinic, especially when administering doses of oncolytic MeV repeatedly.

5. Combination therapies {#sec0025}
========================

5.1. MeV in combination with chemotherapy or other OVs {#sec0030}
------------------------------------------------------

Chemotherapeutics remain at the forefront of cancer therapy. However, their therapeutic potential is limited by considerable toxicity, the occurrence of therapy resistance, and often a lack of durable disease control. With the emergence of MeV as a clinically well-tolerated and promising OV, it is feasible to combine oncolytic MeV with chemotherapy or other treatment modalities to augment tumor clearance ([Fig. 2](#fig0010){ref-type="fig"} ). Preliminary studies by Hoffmann et al. analyzed the combination of MeV fusogenic membrane glycoproteins (FMGs) H and F with chemotherapy as a potentially synergistic therapy approach \[[@bib0465]\]. In this study, pancreatic cancer cells infected with a replication-deficient, FMG-encoding adenovirus (Ad.H/F) in combination with gemcitabine, led to increased apoptotic events and cytotoxicity. Gemcitabine, a pyrimidine nucleoside analog, is frequently used for therapy of various cancers (including pancreatic ductal adenocarcinoma) and has shown synergy with other chemotherapeutics \[[@bib0470]\]. Mice receiving Ad.H/F and gemcitabine had increased survival as well as significantly reduced tumor volumes compared to single-agent treated animals \[[@bib0465]\]. In another study using a xenograft model of colorectal cancer, mice were treated with replication-defective, MeV FMG-encoding adenovirus (Ad.H/F) or herpes virus (HSV.H/F). These vectors were given alone or in combination with the chemotherapy regimen FOLFOX (folinic acid, 5-fluorouracil, oxaliplatin) and/or the respective trans-complementing, oncolytic adeno- or HSV vectors (enabling replication and intra-tumoral spread of otherwise replication-deficient Ad.H/F or HSV.H/F) \[[@bib0475]\]. In this study, triple combination therapy had the highest treatment efficacy compared to either single or double agent regimens. Collectively, intratumoral expression of MeV FMGs can synergize with chemotherapy to improve therapeutic outcomes.Fig. 2**Combination therapies involving oncolytic MeV.** OVs in general, and MeV in particular, can be combined successfully with a variety of alternative treatment modalities, as displayed here.Fig. 2

More recently, replication-competent MeV has been combined with various therapeutics, including gemcitabine. An enhanced cytotoxic effect was observed in non-small cell lung cancer cells treated (*in vitro*) with a combination of gemcitabine and MeV, compared to single-agent treatment \[[@bib0480]\]. A combination of MeV and senescence inducing chemotherapeutics, such as gemcitabine, accelerates lysis of senescent cancer cells in various tumor types \[[@bib0485],[@bib0490]\]. Co-treatment of MeV with low-dose camptothecin resulted in enhanced cytotoxicity in breast cancer cells and demonstrated the potential for a less toxic combination therapy \[[@bib0495]\]. In another study, triple chemo-viro-radiotherapy with MeV, temozolomide, and radiotherapy was shown to exert synergistic anti-glioma activity while inducing a pro-inflammatory phenotype \[[@bib0500]\]. In this context, we have demonstrated that a triple combination approach of MeV armed with a prodrug convertase (PNP) and delivered with the prodrug fludarabine with the chemotherapeutic cyclophosphamide resulted in complete tumor regression *in vivo* \[[@bib0300]\]. The combination of paclitaxel and recombinant MeV encoding BNiP3, a pro-apoptotic gene, was found to increase toxicity and apoptotic activity in breast cancer cells as well \[[@bib0505]\]. It should be noted that the individual combination of an OV with a chemotherapeutic drug, as well as the timing of their administration, needs to be carefully optimized for synergy. In some cases, however, chemotherapeutics can in fact antagonize the efficacy of immunovirotherapy, as recently described for the combination of IL-12-encoding HSV1 and temozolomide \[[@bib0510]\].

Synergy of MeV with other OVs has also been observed. For instance, the combination of measles and mumps virus has been found to increase oncolysis in various solid tumors and hematological malignancies *in vitro, ex vivo,* and *in vivo*, compared to stand-alone therapies \[[@bib0515],[@bib0520]\]. Administration of MeV-CEA and MeV-NIS was found to decrease tumor burden compared to MeV-CEA alone, and also presents the possibility of dual non-invasive monitoring of virus spread *via* the soluble CEA peptide and NIS-based radioiodine imaging \[[@bib0525]\].

Altogether, these findings demonstrate that various combinatorial methods can enhance the efficacy of MeV-based virotherapy.

5.2. MeV in combination with radiotherapy {#sec0035}
-----------------------------------------

Combination of radiotherapy (RT) and MeV was tested mostly in glioblastoma cell lines \[[@bib0500],[@bib0530]\]. The sequence in which RT and MeV are administered is critical to ensure the best outcome, with RT following MeV infection showing the greatest synergistic effect \[[@bib0500],[@bib0530]\]. The mechanism underlying the synergy between RT and MeV combined therapy involves increased apoptosis through activation of FAS receptor signaling which in turn activates extrinsic caspase-8 pathways \[[@bib0530]\]. This synergistic cytotoxic effect was also seen *in vivo*, with enhanced tumor regression and survival, and, in some cases, complete and durable tumor eradication \[[@bib0530]\].

Moreover, chemotherapy in conjunction with RT and MeV may improve treatment outcomes even further. In particular, temozolomide (TMZ) and lomustine (CCNU), chemotherapies frequently used against glioblastoma, showed promise in this regard \[[@bib0500]\]. Maximal synergistic anti-tumor effects were found in a treatment regimen using either TMZ or CCNU first, followed by MeV infection, and then RT \[[@bib0500]\]. Triple combination therapy boosted anti-tumor effects even with cell lines that are resistant to one of the monotherapies \[[@bib0500]\]. A strong increase in IFN-β expression, antigen presentation, and the induction of pro-inflammatory cytokines ultimately enhanced the anti-tumor immune response \[[@bib0500]\].

5.3. MeV in combination with small molecules or metabolic reprograming {#sec0040}
----------------------------------------------------------------------

There are various mechanisms by which small molecules can enhance the therapeutic efficacy of MeV. These include dampening the cellular anti-viral response, altering metabolic pathways, or boosting the induction of apoptosis. In the following chapter, we will highlight some of these pharmaco-virotherapy approaches.

Epigenetic perturbations, and particularly histone modifications as key regulators of epigenetics, play a critical role in the development of cancer \[[@bib0535],[@bib0540]\]. Indeed, resminostat, an inhibitor of class I and IIb histone deacetylase (HDAC) isoenzyme, has shown promising results in phase I/II clinical trials for the treatment of advanced-stage hepatocellular carcinoma (HCC) \[[@bib0545]\]. The combination of resminostat and MeV in HCC and pancreatic cancer cell lines enhanced anti-tumor activity of MeV and resulted in a 20--50 % reduction in cell viability compared to either monotherapy \[[@bib0550],[@bib0555]\]. This enhanced efficacy of the combination therapy occurs through a more pronounced activation of intrinsic apoptotic pathways \[[@bib0555]\]. Interestingly, resminostat does not boost virus replication or spread but instead enhances the rate of primary infection without altering the MeV-induced IFN response \[[@bib0550],[@bib0555]\]. Likewise, MeV did not interfere with the pharmacological function of resminostat as an HDAC inhibitor \[[@bib0550],[@bib0555]\].

Pharmacological targeting of direct or indirect regulators of the cytoskeleton and mitotic spindle dynamics with, for instance, geldanamycin (GA), Y27632, or alisertib, is a common approach in cancer therapy. Geldanamycin (GA) is a heat shock protein 90 inhibitor that is ultimately thought to inactivate RhoA, a protein centrally involved in actin cytoskeleton dynamics \[[@bib0560]\]. Y27632 inhibits the RhoA downstream effector, Rho-associated coiled-coil-forming kinase (ROCK) \[[@bib0565]\]. Alisertib is a highly selective small-molecule inhibitor of the serine/threonine protein kinase Aurora A kinase \[[@bib0570]\]. Inhibition of Aurora A kinase results in a dysregulation of the mitotic spindle apparatus and thus chromosome segregation \[[@bib0570]\]. In breast, ovarian, rhabdomyosarcoma, and glioma cell lines treated with GA or Y27632 in combination with MeV, the number and average size of syncytia were increased \[[@bib0575],[@bib0580]\]. In breast and glioma cell lines \[[@bib0580]\], these effects resulted from the disruption of the actin cytoskeleton and ultimately increased the anti-tumor effect of MeV. GA is known to increase apoptosis through the activation of extrinsic apoptotic pathways \[[@bib0575]\]. Indeed, the increased efficacy of MeV in combination with GA was not due to increased virus replication; instead, it was caused by GA-induced inactivation of RhoA and the consequent downstream dysregulation of cytoskeletal dynamics, transcriptional processes, and cell cycle progression which ultimately boosts syncytia formation and apoptosis \[[@bib0575]\]. Y27632 on the other hand, exerts its effect by enhancing MeV replication in a dose-dependent manner *in vitro*, which was further confirmed *in vivo* using a breast cancer mouse model \[[@bib0580]\]. Treating breast cancer cell lines with alisertib before MeV infection was shown to kill 97 % of cells at a low MOI, boosted virus replication 4-fold, and increased IL-24 expression \[[@bib0585]\]. The combination of alisertib with MeV *in vivo* led to higher survival rates compared to either monotherapy in a pleural effusion model of advanced breast cancer \[[@bib0585]\].

Targeting metabolism is another approach to eradicate cancer cells. It is well known that cancer cells alter metabolic processes to increase glucose uptake and promote fermentation of glucose to lactate, resulting in enhanced survival \[[@bib0590]\]. Selective interference with cellular metabolic processes can be combined with MeV for boosting its anti-tumor efficacy. In this context, alteration of glycolytic pathways with dichloroacetate (DCA) inhibits the conversion of pyruvate to lactate, thereby lowering the lactate level, glucose uptake, and ATP production \[[@bib0595]\]. DCA and MeV co-treatment resulted in a shortage of bioenergetic supplies, which induced necrosis in the tumor cells \[[@bib0595]\]. Additionally, DCA enhanced MeV replication by reducing the expression of key players of the anti-viral response, including IFNB1, CXCL10, MAVS, and phosphorylated IRF3, which led to increased tumor control in a glioblastoma model \[[@bib0595]\]. Similarly, human colorectal cancer cells subjected to long-term low-serum, glucose starvation potentiated the effects of MeV oncolysis compared to non-cancerous cells, suggesting differential stress resistance in healthy and tumor cells \[[@bib0600]\].

5.4. MeV in combination with systemic immunotherapies {#sec0045}
-----------------------------------------------------

The aim of oncolytic immunotherapy is to increase the immune system's anti-tumor response, as well as to antagonize the immunosuppressive TME, which hinders therapeutic efficacy \[[@bib0605]\]. Combination of various immunotherapies with the pro-inflammatory MeV presents the possibility for synergy leading to enhanced therapeutic outcomes. A study by Chen et al. investigated the ability of MeV to improve adoptive CD8^+^ NKG2D^+^ cells against hepatocellular carcinoma (HCC) \[[@bib0610]\]. In HCC cells lines, MeV was found to increase anti-tumor activities of CD8^+^ NKG2D^+^ cells. Intratumoral injection of MeV followed by intravenous transfer of CD8^+^ NKG2D^+^ cells in HCC-bearing mouse models resulted in increased anti-tumor activity, inhibited HCC growth, and led to a significantly increased survival \[[@bib0610]\]. A caveat of this combinatorial approach was its capacity to induce expression of large amounts of the immune-suppressive enzyme IDO1. Additional administration of fludarabine, a chemotherapeutic agent, was able to successfully decrease levels of induced IDO1, demonstrating the importance of addressing therapy-induced immune suppression \[[@bib0610]\]. Another combinatorial approach employed oncolytic MeV with activated human NK cells, which resulted in increased release of NK cell cytolytic enzymes, and enhanced sarcoma cell destruction compared to monotherapies *in vitro* \[[@bib0615]\]. The separate administration of systemic checkpoint inhibitors and MeV has also been successful *in vitro* and *in vivo*. In the early stages of human glioma cell infection with MeV-NIS, an initial upregulation of PD-L1 was noted, demonstrating the immunosuppressive nature of gliomas and the logical approach of anti-PD-1 therapy. In the later stages of MeV-NIS infection, glioma cells release damage-associated molecular patterns (DAMPs). In mice bearing orthotopic GL261 gliomas, the combination of a MeV retargeted against EGFR (administered i.t.) and anti-PD-1 treatment (administered i.p.) enhanced survival, compared to stand-alone therapy or untreated mice, as a result of increased CD8^+^ T cell influx to tumor sites \[[@bib0335]\].

5.5. Measles virus as a vaccine platform {#sec0050}
----------------------------------------

For over half a century, the widespread administration of the live attenuated MeV vaccine has greatly reduced the number of measles-related deaths and has demonstrated lifelong protection against infection accompanied by minimal side effects \[[@bib0620],[@bib0625]\]. In addition to this excellent safety profile, the ability to generate recombinant MeV vectors from the various existing measles vaccine strains presents the possibility of generating vectors for immunization against a wide range of viruses. Specifically, MeV vectors have been pre-clinically developed as vaccines against chikungunya virus (CHIKV) \[[@bib0630]\], dengue virus \[[@bib0635], [@bib0640], [@bib0645]\], hepatitis B virus (HBV) \[[@bib0650], [@bib0655], [@bib0660]\], hepatitis C virus (HCV) \[[@bib0665]\], HIV \[[@bib0670], [@bib0675], [@bib0680], [@bib0685]\], human papillomavirus (HPV) \[[@bib0690],[@bib0695]\], MERS \[[@bib0700],[@bib0705]\], SARS \[[@bib0710],[@bib0715]\], Nipah virus \[[@bib0720]\], respiratory syncytial virus \[[@bib0725], [@bib0730], [@bib0735]\], West Nile virus \[[@bib0740],[@bib0745]\], and Zika virus \[[@bib0750]\]. MeV-CHIKV has successfully completed phase I clinical trials and is progressing through phase II testing (NCT03028441, NCT02861586, NCT03635086). Additionally, the therapeutic effects of MeV-ZIKA (NCT02996890, NCT04033068), MeV-Lassa virus (NCT04055454), and recombinant HIV measles vaccine vector (NCT01320176) are being evaluated at various stages of clinical trials. Currently, we and others are working on the development and clinical translation of a MeV-vectored COVID-19 vaccine.

6. Concluding remarks {#sec0055}
=====================

Oncolytic immunotherapeutics have come a long way from being an unusual concept to being one of the most innovative and promising novel immunotherapeutics in cancer therapy. This shift in perception of OVs from oddities to viable therapeutic modalities has strengthened considerably with the FDA and EMA approval of Talimogene laherparepvec, an engineered oncolytic herpes simplex virus encoding GM-CSF, for the treatment of advanced-stage melanoma. Following this breakthrough for the field, a large variety of OVs based on very different virus families and strains are being developed pre-clinically or are currently being evaluated in clinical trials. As we have discussed here, vaccine strain-derived oncolytic MeV are among the most promising OV candidates. They have an excellent safety record, can be genetically engineered on multiple levels, and have successfully been combined with various established treatment regimens. Multiple phase I-II clinical trials with oncolytic MeV are currently ongoing and the first reported data seem promising. Some of the crucial questions for the next years will be: How can we select the patients who could benefit most from OV therapy? Can we elucidate the molecular principles that are divergent between responding and non-responding patients? Can we exploit this knowledge to engineer next-generation viruses or conceive combination therapies that are successful in patients who do not respond to currently available therapies? We strongly believe that OVs, and oncolytic MeV in particular, can be further developed and translated into a modern immunotherapy for the benefit of cancer patients.
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